Maryanoff B E, Costanzo M J, Nortey S O, Greco M N, Shank R P, Schupsky J J, Ortegon M P, Vaught J L
Drug Discovery, The R. W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477, USA.
J Med Chem. 1998 Apr 9;41(8):1315-43. doi: 10.1021/jm970790w.
We have explored the structure-activity relationship (SAR) surrounding the clinically efficacious antiepileptic drug topiramate (1), a unique sugar sulfamate anticonvulsant that was discovered in our laboratories. Systematic structural modification of the parent compound was directed to identifying potent anticonvulsants with a long duration of action and a favorable neurotoxicity index. In this context, we have probed the pharmacological importance of several molecular features: (1) the sulfamate group (6-8, 22-25, 27, 84), (2) the linker between the sulfamate group and the pyran ring (9, 10, 21a,b), (3) the substituents on the 2,3- (58-60, 85, 86) and 4, 5-fused (30-38, 43, 45-47, 52, 53) 1,3-dioxolane rings, (4) the constitution of the 4,5-fused 1,3-dioxolane ring (2, 54, 55, 63-68, 76, 77, 80, 83a-r, 84-87, 90a, 91a, 93a), (5) the ring oxygen atoms (95, 96, 100-102, 104, 105), and (6) the absolute stereochemistry (106 and 107). We established the C1 configuration as R for the predominant alcohol diastereomer from the highly selective addition of methylmagnesium bromide to aldehyde 15 (16:1 ratio) by single-crystal X-ray analysis of the major diastereomer of sulfamate 21a. Details for the stereoselective syntheses of the hydrindane carbocyclic analogues 95, 96, 100, and 104 are presented. We also report the synthesis of cyclic imidosulfites 90a and 93a, and imidosulfate 91a, which are rare examples in the class of such five-membered-ring sulfur species. Imidosulfite 93a required the preparation and use of the novel sulfur dichloride reagent, BocN=SCl2. Our SAR investigation led to the impressive 4,5-cyclic sulfate analogue 2 (RWJ-37947), which exhibits potent anticonvulsant activity in the maximal electroshock seizure (MES) test (ca. 8 times greater than 1 in mice at 4 h, ED50 = 6.3 mg/kg; ca. 15 times greater than 1 in rats at 8 h, ED50 = 1.0 mg/kg) with a long duration of action (>24 h in mice and rats, po) and very low neurotoxicity (TD50 value of >1000 mg/kg at 2 h, po in mice). Cyclic sulfate 2, like topiramate and phenytoin, did not interfere with seizures induced by pentylenetetrazole, bicucculine, picrotoxin, and strychnine; also, 2 was not active in diverse in vitro receptor binding and uptake assays. However, 2 turned out to be a potent inhibitor of carbonic anhydrase from different rat tissue sources (e. g., IC50 of 84 nM for the blood enzyme and 21 nM for the brain enzyme). An examination of several analogues of 2 (83a-r, 85-87, 90a, 91a, 93a) indicated that potent anticonvulsant activity is associated with relatively small alkyl substituents on nitrogen (Me/H, 83a; Me/Me, 83m; Et/H, 83b; allyl/H, 83e; c-Pr/H, 83j; c-Bu/H, 83k) and with limited changes in the cyclic sulfate group, such as 4,5-cyclic sulfite 87a/b. The potent anticonvulsants 83a and 83j had greatly diminished carbonic anhydrase inhibitory activity; thus, inhibition of this enzyme may not be a significant factor in the anticonvulsant activity. The alpha-L-sorbopyranoses 67, 68, and 80, which mainly possess a skew conformation (ref 29), were nearly twice as potent as topiramate (1). The L-fructose enantiomers of 1 (106) and 2 (107), synthesized from L-sorbose, were found to have moderate anticonvulsant activity, with eudysmic ratios (MES ED50 in mice at 4 h, po) of 1:106 = 1.5 and 2:107 = 3.5. The log P values for 1 and 2 were determined experimentally to be 0.53 and 0.42, respectively, which are less than the optimal 2.0 for CNS active agents. However, analogues with more favorable calculated log P (clogP) values, in conjunction with just minor steric perturbation according to the developed SAR profile, such as 47 (clogP = 2.09), 83m (1.93), and 86 (1.50), did not display improved potency: 47 is less potent than 1, 83m is equipotent with 2, and 86 is less potent than 2. Although the measured log P value for diethyl analogue 31 is 1.52, this did not translate into enhanced potency relative to 1. (ABSTRACT TRUNCATED)
我们已经探究了临床有效的抗癫痫药物托吡酯(1)的构效关系(SAR),托吡酯是一种独特的糖氨基磺酸盐抗惊厥药,是在我们实验室中发现的。对母体化合物进行系统的结构修饰旨在鉴定出作用时间长且神经毒性指数良好的强效抗惊厥药。在此背景下,我们探究了几个分子特征的药理学重要性:(1)氨基磺酸酯基团(6 - 8、22 - 25、27、84),(2)氨基磺酸酯基团与吡喃环之间的连接基团(9、10、21a、b),(3)2,3 - (58 - 60、85、86)和4,5 - 稠合(30 - 38、43、45 - 47、52、53)1,3 - 二氧戊环环上的取代基,(4)4,5 - 稠合1,3 - 二氧戊环环的组成(2、54、55, 63 - 68、76、77、80、83a - r、84 - 87、90a、91a、93a),(5)环上的氧原子(95、96、100 - 102、104、105),以及(6)绝对立体化学(106和107)。通过对氨基磺酸酯21a的主要非对映异构体进行单晶X射线分析,我们确定了来自高度选择性的甲基溴化镁与醛15加成(比例为16:1)的主要醇非对映异构体的C1构型为R。本文介绍了氢化茚碳环类似物95、96、100和104的立体选择性合成细节。我们还报道了环状亚胺基亚硫酸盐90a和93a以及亚胺基硫酸盐91a的合成,它们是此类五元环硫物种中的罕见例子。亚胺基亚硫酸盐93a需要制备和使用新型二氯化硫试剂BocN = SCl2。我们的构效关系研究得到了令人印象深刻的4,5 - 环状硫酸盐类似物2(RWJ - 37947),其在最大电休克惊厥(MES)试验中表现出强效抗惊厥活性(在小鼠中4小时时约为1的8倍,ED50 = 6.3 mg/kg;在大鼠中8小时时约为1的15倍,ED50 = 1.0 mg/kg),作用时间长(小鼠和大鼠口服时>24小时)且神经毒性非常低(小鼠口服2小时时TD50值>1000 mg/kg)。环状硫酸盐2与托吡酯和苯妥英一样,不干扰由戊四氮、荷包牡丹碱、印防己毒素和士的宁诱导的惊厥;此外,2在各种体外受体结合和摄取试验中均无活性。然而,2被证明是来自不同大鼠组织来源的碳酸酐酶的强效抑制剂(例如,血液酶的IC50为84 nM,脑酶的IC50为21 nM)。对2的几个类似物(83a - r、85 - 87、90a、91a、93a)的研究表明,强效抗惊厥活性与氮上相对较小的烷基取代基(Me/H,83a;Me/Me,83m;Et/H,83b;烯丙基/H,83e;环丙基/H,83j;环丁基/H,83k)以及环状硫酸盐基团的有限变化有关,例如4,5 - 环状亚硫酸盐87a/b。强效抗惊厥药83a和83j的碳酸酐酶抑制活性大大降低;因此,抑制该酶可能不是抗惊厥活性的重要因素。主要具有扭曲构象(参考文献29)的α - L - 山梨吡喃糖67、68和80的效力几乎是托吡酯(1)的两倍。由L - 山梨糖合成的1(106)和2(107)的L - 果糖对映体具有中等抗惊厥活性,优效比(小鼠口服4小时时的MES ED50)为1:106 = 1.5和2:107 = 3.5。实验测定1和2的log P值分别为0.53和0.42,低于中枢神经系统活性剂的最佳值 2.0。然而,根据所建立的构效关系图谱具有更有利计算log P(clogP)值且仅具有轻微空间扰动的类似物,例如47(clogP = 2.09)、83m(1.93)和86(1.50),并未表现出提高的效力:47比1效力低,83m与2效力相当,86比2效力低。尽管二乙基类似物31的实测log P值为1.52,但相对于1而言,这并未转化为增强的效力。(摘要截断)